Quest Introduces Novel Rheumatoid Arthritis Blood Tests

Quest Diagnostics (NYSE:DGX), a leading provider of diagnostic information services, has launched 2 new blood tests that will help in the early diagnosis of rheumatoid arthritis.

As quoted in the press release:

The lab-developed tests are based on the proprietary 14-3-3eta protein biomarker through an exclusive license agreement for the U.S. market with Augurex Life Sciences.  One test provides results of 14-3-3eta blood levels, while a comprehensive panel provides results of blood levels of the novel marker as well as the conventional RA markers cyclic citrullinated peptide (CCP) antibodies and rheumatoid factor (RF). Higher blood levels may suggest a greater likelihood of RA.

Click here to read the full Quest Diagnostics (NYSE:DGX) press release.